To the Editor:
In a retrospective, nonrandomized subanalysis of the single-center REMADHE trial, Issa et al 1 suggest that ␤-blockers may improve survival among patients with heart failure of chagasic etiology and that physicians should not hesitate to prescribe them. However, this beneficial effect may have arisen due to chance (P valueϭ0.05) because of a small sample (only 68 patients, 24 on and 44 off ␤-blockers) or to differences in baseline characteristics (eg, more males and fewer patients using angiotensin-converting enzyme inhibitors and spironolactone in the non-␤-blocker group), because ␤-blocker use was not determined randomly. Moreover, the baseline data regarding other important prognostic markers (eg, New York Heart Association class, cardiomegaly, and non-sustained ventricular tachycardia [NSVT]) were not provided. Of note, when the sample size is small, even nonstatistically significant differences in baseline characteristics may still be large enough to exert a substantial effect on the outcome. From the analysis description, it seems that adjustments for confounders were not performed. Also, in some patients, ␤-blockers may have not been prescribed because of contraindications (eg, bradycardia, atrioventricular blocks, hypotension, and lung disease), which already identify them as a higher risk group.
Another key issue that needs to be addressed is the role of amiodarone in this scenario. Episodes of NSVT (a consistent and independent predictor of mortality) are seen in most patients with Chagas cardiomyopathy and heart failure, and according to the Brazilian guidelines, 2 amiodarone should usually be offered to these patients (class IIa indication). Amiodarone markedly reduces the frequency and complexity of ventricular arrhythmias and has been shown to reduce mortality in the only 2 randomized trials that included chagasics patients (EPAMSA and GESICA). It should be noted that the results of SCD-HeFT, a neutral trial for amiodarone, by no means apply to patients with Chagas cardiomyopathy. SCD-HeFT enrolled only patients with coronary artery disease or idiopathic-dilated cardiomyopathy, NSVT (present in only 23% of the patients) was not an entry criterion, and most patients were already on ␤-blockers. Furthermore, the most crucial subgroup analysis (comparing amiodarone versus placebo in patients with and without NSVT) was not performed in SCD-HeFT.
Curiously, the results of another trial (AMIOVIRT), which compared amiodarone versus implantable cardioverter defibrillator (exclusively in patients with NSVT and heart failure of nonischemic etiology) and did not show any superiority of implantable cardioverter defibrillators, were already known before the publication of SCD-HeFT. So, the claim by Issa et al 1 that their findings support the use of ␤-blockers in patients with Chagas cardiomyopathy seems premature and anecdotal. Nevertheless, we agree with the authors that a prospective, randomized trial (comparing amiodarone with ␤-blocker and maybe with both drugs) is urgently needed.
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